Carboplatin

CAS 41575-94-4 12 current records 5 historicalSmall Molecule

Who holds supplier records for Carboplatin? 12 organisations hold a current record for Carboplatin: an active US FDA Type II Drug Master File or a CEP. A further 5 organisations have only historical (inactive) DMF filings. 11 of them hold a valid EU Certificate of Suitability. Recorded organisation countries for current records: India (5), China (2), Germany (1), Netherlands (1) and 2 other countries (2); not recorded for 1.

Sources: FDA Drug Master File list, EDQM certification database, FDA Orange Book. Record updated 16 Nov 2026. How we read these records

Cite as: PharmaTek, “Carboplatin: DMF and CEP holder records”, record as of 16 Nov 2026, pharmatek.co.uk/directory/api/carboplatin

Reading the evidence

  • 12 current records

    Several organisations hold current DMFs or CEPs. Whether any is a usable source for your grade, scale and market still needs qualification.

  • 7 with a company-level GMP certificate on record

    These organisations have at least one current EU or UK GMP certificate somewhere. It is not matched to the site that makes this substance; check the certificate's site and scope.

  • US product patents listed

    The latest patent listed in the FDA Orange Book for an approved product containing Carboplatin expires 1 Apr 2045. Product, formulation and method-of-use patents do not by themselves stop the ingredient being supplied or other products being approved.

Current records (12)

Organisations holding an active US FDA Type II Drug Master File or a CEP for Carboplatin. Country is the organisation's recorded country, not necessarily the manufacturing site.

Need Carboplatin sourced and checked?

The Sourcing Desk contacts candidates, confirms current supply, grade and site, and screens each against its regulatory record, for a buyer-paid fixed fee and never a supplier commission.

Request sourcing help

Valid CEP holder entries (11)

Certificates of Suitability on the EDQM register for Carboplatin, including the salts, esters and hydrates the register lists separately; each row shows the substance as named on the certificate. A CEP confirms the substance can be controlled by the European Pharmacopoeia monograph; it is not a GMP certificate, and the holder is not necessarily the manufacturer. 19 certificates in total, including withdrawn, expired, suspended and repeat certificates.

HolderCountryCertificateIssuedEU GMP at holder's address
HETERO LABS LIMITED HyderabadIN
CEP 2026-464 - Rev 00
Carboplatin, Process-II
Nov 2026—
SUN PHARMACEUTICAL INDUSTRIES LIMITED MumbaiIN
CEP 2003-155 - Rev 05
Carboplatin
Mar 2026—
QILU PHARMACEUTICAL CO., LTD. JinanCN
CEP 2010-285 - Rev 05
Carboplatin
Jan 2026Inspected Feb 2025
Switzerland
HERAEUS PRECIOUS METALS GMBH & CO. KG HanauDE
CEP 2002-091 - Rev 09
Carboplatin
Apr 2025Inspected Oct 2025
Germany
TAPI NL B.V. AmsterdamNL
CEP 2000-375 - Rev 05
Carboplatin
Mar 2025—
FRESENIUS KABI ONCOLOGY LIMITED KalyaniIN
CEP 2001-282 - Rev 14
Carboplatin
Aug 2024—
KUNMING GUIYAN PHARMACEUTICAL CO., LTD. KunmingCN
CEP 2009-383 - Rev 04
Carboplatin
Jun 2024—
LAURUS LABS LIMITED HyderabadIN
CEP 2010-348 - Rev 04
Carboplatin
Mar 2024—
VERANOVA, L.P. West DeptfordUS
R1-CEP 2004-104 - Rev 03
Carboplatin
Mar 2023—
UMICORE ARGENTINA S.A. Pilar Industrial ParkAR
R1-CEP 2009-264 - Rev 03
Carboplatin
Oct 2019—
CIPLA LIMITED MumbaiIN
R1-CEP 2005-125 - Rev 03
Carboplatin
Sept 2019—

The GMP column shows the most recent EU GMP certificate issued for the same address as the holder, joined on the EMA location identifier printed on both documents (EudraGMDP, re-read about once a quarter; withdrawn certificates are excluded). A dash means no certificate carries that identifier, not that the site is uninspected. The holder's address is not necessarily where the substance is made.

Certification Online Database. European Directorate for the Quality of Medicines & HealthCare (EDQM), Council of Europe, (2026), URL: https://extranet.edqm.eu/publications/recherches_CEP.shtml. Accessed 16 Nov 2026. Reproduced with permission and unaltered. The EDQM and the Council of Europe accept no liability for any consequence arising from its use.

Historical records (5)

Organisations whose Type II DMFs for Carboplatin are no longer active. These show a past filing, not current supply.

Show all 5 historical records
  • MAC CHEM PRODUCTS INDIA PVT LTD
    Inactive DMF 26029 · filed May 2012
  • INSTITUTE DRUG TECHNOLOGY AUSTRALIA LTD
    Inactive DMF 16709 · filed Jul 2003
  • PLIVA-LACHEMA AS
    Inactive DMF 16280 · filed Dec 2002
  • DEGUSSA AG WERK RADEBEUL
    Inactive DMF 12369 · filed Feb 1997
  • LACHEMA BRNO
    Inactive DMF 9541 · filed Jan 1992

US product patents and exclusivity

The FDA Orange Book lists patents and exclusivities for specific approved products (43 listed products contain Carboplatin). The latest listed patent expires 1 Apr 2045. These dates are product-specific: they can cover a formulation, a combination or a method of use, and do not on their own show whether the ingredient is protected or whether generics are already approved. Check the individual product entries before planning a launch.

Overview

Carboplatin is a chemotherapy medication used to treat various types of cancer. It is a platinum-based compound that interferes with the DNA of cancer cells, inhibiting their growth and division.

Chemical identity

IUPAC name
azane;cyclobutane-1,1-dicarboxylate;platinum(2+)
Canonical SMILES
C1CC(C1)(C(=O)[O-])C(=O)[O-].N.N.[Pt+2]
InChIKey
OLESAACUTLOWQZ-UHFFFAOYSA-L
Synonyms
Paraplatin API, carboplatinum, kyxata, nsc-201345, nsc-241240, paraplatin

Pharmacologic class

As the US FDA states it for this active substance on product listings.

Established pharmacologic class
Platinum-based Drug

Therapeutic areas

OncologyChemotherapyAntineoplastic

Record history

No change to the current records between 13 Nov 2026 and 16 Nov 2026.

Get an email when these records change: at most one a week, only when something changed, and only after you confirm your address. All changes this week

What these records establish

  • An active DMF means a confidential file is held by the FDA and can be referenced; the FDA does not approve or disapprove DMFs.
  • A CEP confirms monograph suitability for the EU market; it is not a GMP certificate, and the holder may not be the manufacturer.
  • Historical records show a past filing, not current supply.
  • Company GMP certificates are matched to the organisation, not to the site making this substance.
  • A substance missing from these registers is not evidence that no supplier exists.

Frequently asked questions

Which organisations hold current supplier records for Carboplatin?

12 organisations hold an active US FDA Type II Drug Master File or a CEP for Carboplatin: KUNMING GUIYAN PHARMACEUTICAL CO LTD (China), HERAEUS PRECIOUS METALS GMBH AND CO KG (Germany), Hetero Labs Limited (India), Laurus Labs Limited (India), Qilu Pharmaceutical Co., Ltd. (China), Sun Pharmaceutical Industries Limited (India), TAPI NL BV (Netherlands) and UMICORE ARGENTINA SA, and 4 more listed on this page. A DMF or CEP shows a regulatory filing, not current commercial availability, and the holder is not necessarily the manufacturing site.

Which Carboplatin Drug Master Files are active?

KUNMING GUIYAN PHARMACEUTICAL CO LTD (DMF 41731, 29100), HERAEUS PRECIOUS METALS GMBH AND CO KG (DMF 15147), Hetero Labs Limited (DMF 29167), Laurus Labs Limited (DMF 21918), Qilu Pharmaceutical Co., Ltd. (DMF 23606, 24201), Sun Pharmaceutical Industries Limited (DMF 16664), TAPI NL BV (DMF 17659) and UMICORE ARGENTINA SA (DMF 28047) and 2 more. The FDA does not approve or disapprove DMFs; an active DMF can be referenced in an application once its holder issues a letter of authorisation.

What do the historical Carboplatin records mean?

5 organisations have only inactive Type II DMFs for Carboplatin. An inactive DMF records that a filing once existed; it does not show that the organisation supplies the substance today.

Does Carboplatin have a European Certificate of Suitability?

Yes. 11 organisations hold a valid CEP for Carboplatin on the EDQM register, including HETERO LABS LIMITED Hyderabad (IN), SUN PHARMACEUTICAL INDUSTRIES LIMITED Mumbai (IN), QILU PHARMACEUTICAL CO., LTD. Jinan (CN), HERAEUS PRECIOUS METALS GMBH & CO. KG Hanau (DE), TAPI NL B.V. Amsterdam (NL) and FRESENIUS KABI ONCOLOGY LIMITED Kalyani (IN) and 5 more. A CEP confirms the substance can be controlled by the European Pharmacopoeia monograph; it is not a GMP certificate, and the holder is not necessarily the manufacturer.

Does the FDA Orange Book list patents for products containing Carboplatin?

Yes. The latest patent listed for an approved US product containing Carboplatin expires 1 Apr 2045, across 43 listed products. These patents protect specific products, formulations or uses. They do not by themselves mean the ingredient is protected, and generic versions of other products may already be approved.

How do I qualify a Carboplatin supplier?

Confirm the DMF or CEP is current and covers your grade, obtain the letter of authorisation, identify the actual manufacturing site and check its GMP certificate and FDA inspection history, audit the site or review a recent audit, and run comparable requests for information across more than one candidate.

For suppliers

Do you supply Carboplatin?

Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.

Free. Payment never buys an evidence status.